Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MB-105 |
| Synonyms | |
| Therapy Description |
MB-105 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD5, which potentially induces cytotoxicity against CD5-expressing tumor cells (Blood (2024) 144 (Supplement 1): 7223, NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MB-105 | MB 105|MB105 | CD5 Immune Cell Therapy 4 | MB-105 comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD5, which potentially induces cytotoxicity against CD5-expressing tumor cells (Blood (2024) 144 (Supplement 1): 7223, NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06534060 | Phase II | MB-105 | MB-105 in Patients With CD5 Positive T-cell Lymphoma | Recruiting | USA | 0 |